JSA advised Serum Institute of India Private Limited (“Serum”), in its sale of 35% stake in Schott Poonawalla Private Limited (“Schott Poonawalla”) to TPG Scion Unit Trust (acting through its trustee Scion Trustee Limited) (“TPG”). Schott Poonawalla is a joint venture between Serum and the Schott group – pursuant to the proposed sale, the Schott group remains a majority shareholder in Schott Poonawalla, while Serum and TPG will hold 15.01% and 34.99%, respectively. The transaction was subject to CCI approval, which was successfully received last month. JSA was assisted by Gibson, Dunn & Crutcher LLP on the anti-bribery and anti-corruption-related aspects of the transaction.
SCHOTT Poonawalla is India’s largest injectables-focused drug containment solutions company, offering a comprehensive product portfolio of the highest quality for over two decades.
Our transaction team comprised Lead Partner & National Corporate Lead, Iqbal Khan, Partner, Devika Menon, Senior Associate, Subbalaxmi S and Associate, Gunjan Singh.
Our competition team comprised Partner and Chair, Competition Law, Nisha Kaur Uberoi, Principal Associate, Rahat Dhawan, Senior Associate, Rishi Kauntia and Associate, Cherian Chacko Manayath.
Media coverage – Business Standard
Iqbal Khan is a Partner and National Corporate Head at JSA, with a key role in Private Equity, Mergers & Acquisitions and Joint Venture Practices.